In light of the foregoing we attempted to improve the delivery of lipoplexes targeting C1858T PTPN22 gene variant (LiposiRNA or L-siRNA (DMPC/2/siRNA), vide infra) by functionalization with the Sig10L sialic acid mimetic (SAM) to achieve selective immunomodulation in Siglec-10 expressing immunocytes for personalized immunotherapy in patients affected by endocrine autoimmunity with special reference to T1D. The gene discussed is PTPN22; the disease is type 1 diabetes mellitus.